ArticleFrontiers in genetics2025
Uncovering differential gene expression between mtRNA-positive and -negative osteosarcoma cells: implications beyond mitochondrial function.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long-term clinical outcomes for patients with osteosarcoma have shown little improvement over the past few decades. Identifying novel molecular targets to inhibit osteosarcoma cell growth remains an urgent challenge. Methods: Explore the function of mtRNA in the occurrence and development of osteosarcoma utilizing bioinformatics analysis of the Gene Expression Omnibus (GEO) microarray dataset. The Network Analyst tool was used to analyze GSE73120. Differentially expressed genes (DEGs) were identified using GEO2R and analyzed using NetworkAnalyst. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were performed using Metascape and WebGestalt. A protein-protein interaction (PPI) network was constructed through the STRING database and visualized with Cytoscape. The MCODE algorithm was used to identify key modules, and CytoHubba was applied to determine hub genes. Validation of hub genes was conducted using the GEPIA database. Results: A total of 104 DEGs were identified, including 89 upregulated and 15 downregulated genes. GO and KEGG analyses revealed that these DEGs were enriched in pathways related to connective tissue development, collagen trimer, and extracellular matrix structural components. The PPI network analysis identified seven hub genes. Among them, COL1A1, PDGFRB, and SPARC were confirmed as sarcoma-related genes using the GEPIA database. Conclusion: Our findings suggest that COL1A1, PDGFRB, and SPARC may be involved in mtRNA-driven tumorigenesis and could serve as promising therapeutic targets for osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.